Bruker has agreed to acquire preclinical imaging business from Oncovision for an undisclosed sum.
Under the deal, Oncovision will hold its clinical human imaging business, including the breast cancer diagnostic device Mammi PET.
During the last five years, both firms have partnered to market Albira PET/SPECT/CT systems, as well as developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology for enhanced full field-of-view PET resolution and sensitivity.
The companies have also worked together on a preclinical 3 Tesla SiPM-PET/MRI system.
In addition, the firms will showcase a new simultaneous SiPM-PET/MR insert for high-field magnets at WMIC 2016 in New York.
Subject to closing conditions, the deal is expected to complete in the fourth quarter of this year.
Bruker preclinical imaging division president Dr Wulf I. Jung said: “This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging.
“Our successful collaboration with Oncovision has led to the recent introduction of the performance-leading Albira Si PET/SPECT/CT system, and it now has also resulted in the first PET insert for high-field MRI systems for simultaneous PET and MRI measurements.”
Oncovision CEO Ignasi Vivas said: “The combined resources will accelerate the development and integration of Bruker's molecular imaging technologies, and fulfill the growing demand from translational scientists.”
Oncovision produces medical imaging devices for the diagnosis and treatment of cancer.
With offices in Boston of US and Valencia of Spain, the company sells its products in around 30 markets.
Image: Albira Si with advanced Silicone photomultiplier technology for highest full field-of-view PET resolution and sensitivity. Photo: courtesy of Bruker Corporation.